News

Data from the MS SMART trial, which may serve as a template for simultaneous testing of multiple DMTs, suggest that exclusively targeting axonal pathobiology is inadequate to prevent neuroaxonal loss.

New study data showed nerve ultrasound had a sensitivity of 97.4% and specificity of 78.9%, with an added value in the detection of treatment-responsive chronic inflammatory neuropathy of 21.1%.

Seizure-free patients experienced similar rates of graduation and employment following epilepsy surgery compared to the general population.

The president of the American Epilepsy Society and director of epilepsy research at Brigham and Women’s Hospital outlined the state of epilepsy care and what we can expect in 2020.

Those taking the drug achieved a significant reduction in the risk of stroke and death after acute ischemic stroke or transient ischemic attack when coupling it with aspirin.

The director of the Pediatric Epilepsy Program is joined by an MD candidate from Weill Cornell Medicine to discuss the protocol used to treat patients with status epilepticus.

Findings from a study revealed that 50% of strokes in adolescents remained cryptogenic, sparking the need for multidisciplinary collaboration on prevention and management.

Retrospective study data suggest that among women aged 13 to 50 years with idiopathic generalized epilepsy, avoiding valproate resulted in a higher likelihood of unsatisfactory seizure control.

The Infinity DBS system is the only directional DBS system approved to target all major areas associated with movement disorders, including Parkinson disease and essential tremor.

The phase 2 clinical trial of CAD-1883 will assess the efficacy and safety of the drug compared to placebo.

Neurology News Network for the week ending January 27, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 24, 2020.

The epilepsy fellow at the hospital of the University of Pennsylvania detailed why locating the seizure onset zone plays a crucial role in successful epilepsy surgery.

Caregivers who care for children with frequent seizures experienced the greatest economic deficit, begging the question whether epilepsy interventions should be weighed based on cost/benefit.

Subgroups and treatment-related changes can be identified with comparative cerebrospinal fluid proteomic analysis in adult patients with spinal muscular atrophy who are treated with nusinersen.

A systematic review of 9 studies suggested that pretreatment with dual antiplatelet therapy is not associated with a higher risk of poor outcomes after intravenous thrombolysis.

The first trial of its kind in amyotrophic lateral sclerosis will first examine 3 drugs and add additional treatments as more become available.

Part 2 of the pivotal FIREFISH clinical trial met its primary end point in infants aged 1 to 7 months with Type 1 spinal muscular atrophy, with statistically significant and medically meaningful motor milestone improvements.